Martek Biosciences Corporation (Nasdaq: MATK) announced that a jury in the U.S. District Court in Wilmington, Delaware, has returned a verdict favorable to Martek in its patent infringement suit against Lonza Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH.
The jury found that Lonza infringed all the asserted claims and found that Lonza had acted willfully in its infringement of one of the patents. The verdict does not involve Martek’s core infant formula patents. Martek expects Lonza to appeal the jury’s decision. Martek intends to ask the Court for permanent injunctive relief to prohibit Lonza’s continuing infringement of the patents.
“We are gratified the jury found that Martek’s patents pertaining to omega-3 DHA products and processes are valid and enforceable and that Lonza’s actions infringe on those patents. The verdict further demonstrates both the Company’s resolve to vigorously defend our intellectual property portfolio and the strength of Martek’s patent portfolio in the U.S. marketplace,” said Steve Dubin, CEO of Martek.
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the development of DHA omega-3 products.
Loading...